MedPath

Computer Assisted Vasopressor Titration in Critically Ill Patients

Not Applicable
Completed
Conditions
Closed-Loop Communication
Interventions
Device: closed-loop system for vasopressor administration
Registration Number
NCT04106791
Lead Sponsor
Erasme University Hospital
Brief Summary

The purpose of this pilot study is to evaluate the performance of a novel closed-loop (automated) vasopressor administration system that delivers norepinephrine using feedback from standard operating room hemodynamic monitor (EV1000 Monitor-Flotrac Edwards Lifesciences, IRVINE, USA) in 10 to 12 critically ill patients in the intensive care unit.

Detailed Description

The investigators have developed an automated closed-loop system for vasopressor administration . They will test it in critically ill patients. The investigators want to demonstrate that the closed-loop system can maintain mean arterial pressure ( MAP) within a very narrow range (within +/- 5 mmHg of the predefined MAP target) for more than 85 % of the treatment time.

The Investigators have shown this to be the case in simulation studies and in-vivo animal studies and in surgical patients but not yet in the Intensive care unit (ICU). Investigators will recruit 10 to 12 ICU patients equipped with a mini-invasive cardiac output monitoring and under continuous norepinephrine infusion.

These patients will typically include: septic patients, neuro ICU patients, ARDS patients, trauma patients or postoperative patients.

The target MAP will be determined by the ICU physician in charge of the patient.

Fluids will be given standard of care. The closed loop (automated) system will use an infusion pump (Q-Core and chemyx pump) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments of vasopressor (norepinephrine)

The goal is to register a period of two hours of closed-loop control of MAP.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • ICU patients under norepinephrine administration and equipped with a advanced hemodynamic monitoring device
Exclusion Criteria
  • Subjects under 18 years of age
  • Subjects not requiring cardiac output monitoring or an arterial line
  • Subject with Atrial Fibrillation
  • Subjects who are pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Closed-loopclosed-loop system for vasopressor administrationPilot study: one single group of 10 ICU patients.
Primary Outcome Measures
NameTimeMethod
Percentage of case Time in target (MAP within 5 mmHg of the predetermined MAP target).48 hours post-admission in the intensive care

The primary outcome will be the percentage of case time in target

Secondary Outcome Measures
NameTimeMethod
Percentage of case Time in hypotension (MAP <5 mmHg of the chosen target)48 hours post-admission in the intensive care

Percentage of case Time in hypotension (MAP \<5 mmHg of the chosen target)

Percentage of case time with MAP >5 mmHg of the chosen target with vasopressor still running.48 hours post-admission in the intensive care

Percentage of case time with MAP \>5 mmHg of the chosen target with vasopressor still running.

Limitations of the closed-loop system48 hours post-admission in the intensive care

Number of errors, malfunction of the system during the treatment time

Amount of vasopressors received48 hours post-admission in the intensive care

Amount of vasopressors received

Number of vasopressor modifications over the treatment time48 hours post-admission in the intensive care

Number of vasopressor modifications (increase or decrease infusion rate) over the treatment time

Trial Locations

Locations (1)

Erasme

🇧🇪

Brussels, Anderlecht, Belgium

© Copyright 2025. All Rights Reserved by MedPath